Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) posted quarterly EBIT Margin of 65.61% for Q2 2024, up 316698.0% year-over-year from N/an in Q3 2023, and up 102.04% quarter-over-quarter from 3213.78% in Q4 2023.
Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EBIT Margin for 5 consecutive years, with 65.61% the latest figure, recorded in Q2 2024.
- In Q2 2024, EBIT Margin rose 316698.0% year-over-year to 65.61%; the TTM figure through Jun 2025 stood at 105.97% (down 6582.0% YoY), while the FY2024 annual figure was 27.37%, up 391787.0% from the prior year.
- EBIT Margin improved to 65.61% in Q2 2024 per FULC's latest filing, from 3213.78% in the prior quarter.
- Across five years, EBIT Margin topped out at 65.61% in Q2 2024 and bottomed at 9471.19% in Q1 2023.
- Historically, EBIT Margin has averaged 2044.08% across 5 years, with a median of 1033.77% in 2020.
- Annual changes were most pronounced in 2023 — EBIT Margin tumbled 846818 bps — and 2024, when it soared 316698 bps.
- Fulcrum Therapeutics' EBIT Margin stood at 420.99% in 2020, then retreated by 11 bps to 465.78% in 2021, then sank by 777 bps to 4083.65% in 2022, then climbed by 21 bps to 3213.78% in 2023, then jumped by 102 bps to 65.61% in 2024.
- Business Quant data shows FULC's EBIT Margin at 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 65.62% |
| Dec 31, 2023 | -3,213.78% |
| Sep 30, 2023 | -3,615.28% |
| Jun 30, 2023 | -3,101.36% |
| Mar 31, 2023 | -9,471.19% |
| Dec 31, 2022 | -4,083.65% |
| Sep 30, 2022 | -2,058.75% |
| Jun 30, 2022 | -1,819.08% |
| Mar 31, 2022 | -1,003.01% |
| Dec 31, 2021 | -465.78% |
| Sep 30, 2021 | -420.87% |
| Jun 30, 2021 | -449.26% |
| Mar 31, 2021 | -355.88% |
| Dec 31, 2020 | -420.99% |
| Sep 30, 2020 | -1,033.77% |
| Jun 30, 2020 | -796.20% |
| Mar 31, 2020 | -2,506.13% |